Related Experiment Video
Updated: Nov 23, 2025
11:51
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
Published on: August 16, 2010
31.1K
A cell-based drug delivery platform for treating central nervous system inflammation
Oren Levy1, Veit Rothhammer2, Ivan Mascanfroni2
1Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA, USA.
Journal of Molecular Medicine (Berlin, Germany)
|January 5, 2021
Summary
Mesenchymal stem cells (MSCs) loaded with Ro-31-8425 effectively treat experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). This cell-based delivery offers sustained drug release and enhanced therapeutic effects compared to free drug administration.
Area of Science:
- Immunology
- Cell Biology
- Pharmacology
Background:
- Mesenchymal stem cells (MSCs) show potential for treating autoimmune diseases like multiple sclerosis (MS).
- Investigating the use of Ro-31-8425, an ATP-competitive kinase inhibitor, with MSCs for enhanced therapeutic delivery.
Purpose of the Study:
- To evaluate the efficacy of Ro-31-8425-loaded MSCs as a drug delivery system for autoimmune inflammatory diseases.
- To assess the impact of MSC-mediated Ro-31-8425 delivery on T cell proliferation and experimental autoimmune encephalomyelitis (EAE) in a murine model.
Main Methods:
- MSCs were pretreated to spontaneously uptake Ro-31-8425, followed by assessment of drug release.
- In vitro studies evaluated the effect of free and MSC-released Ro-31-8425 on CD4+ T cell proliferation.
- In vivo studies utilized experimental autoimmune encephalomyelitis (EAE) mice treated with Ro-31-8425-loaded MSCs, control MSCs, or free Ro-31-8425.
Main Results:
- MSCs efficiently loaded and gradually released Ro-31-8425.
- Ro-31-8425, both free and released by MSCs, suppressed CD4+ T cell proliferation in vitro.
- Systemic administration of Ro-31-8425-loaded MSCs significantly ameliorated EAE symptoms, outperforming free Ro-31-8425 and control MSCs.
- Ro-31-8425-MSC treatment led to sustained serum drug levels and modulated immune responses in EAE mice.
Conclusions:
- MSC-based drug delivery represents a promising strategy for autoimmune diseases.
- Ro-31-8425-loaded MSCs provide sustained therapeutic drug levels and enhanced efficacy in an MS model.
- This approach offers a potential new therapeutic avenue for managing autoimmune inflammatory conditions.
